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STAT3Dysregulated growth and motility of vascular smooth muscle cells (VSMC) play important role in obstructive
vascular diseases. We previously reported that gene transfer of thymidine phosphorylase (TP) into rat VSMC
inhibits cell proliferation and attenuates balloon injury induced neointimal hyperplasia; however, the mech-
anism remains unclear. The current study identiﬁed a signaling pathway that mediates effect of TP inhibited
VSMC proliferation with a TP activity-dependent manner. Rat VSMC overexpressing human TP gene (C2) or
control empty vector (PC) were used. Serum stimulation induced constitutive STAT3 phosphorylation at ty-
rosine705 in C2 cell but not in PC, which was independent of JAK2 signaling pathway. Inhibition of Src family
kinases activity inhibited STAT3 phosphorylation in C2 cells. Lyn activity was higher in C2 cell than in PC.
SiRNA based gene knockdown of Lyn signiﬁcantly decreased serum induced STAT3 phosphorylation in C2
and dramatically increased proliferation of this cell, suggesting that Lyn plays a pivotal role in TP inhibited
VSMC proliferation. Unphosphorylated STAT3 (U-STAT3) expression was signiﬁcantly increased in C2 cells,
which may be due to the increased STAT3 transcription. Gene transfection of mouse wild‐type or Y705F mu-
tant STAT3 into PC cell or mouse primary cultured VSMC signiﬁcantly reduced proliferation of these cells,
suggesting that overexpression of U-STAT3 inhibits VSMC proliferation. We conclude that Lyn mediates TP
induced STAT3 activation, which subsequently contributes to upregulate expression of U-STAT3. The
U-STAT3 plays a critical role in inhibiting VSMC proliferation.
© 2012 Elsevier B.V. All rights reserved.TP, Thymidine phosphorylase;
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Dysregulated growth and motility of vascular smooth muscle cells
(VSMCs) contribute to neointimal lesion development during the
pathogenesis of obstructive vascular diseases, such as atherosclerosis,
restenosis after percutaneous transluminal coronary angioplasty,
stent graft implantation, and vascular graft failure after coronary ar-
tery bypass graft surgery. Therefore, targeting VSMCs to prevent pro-
liferation and migration may be sufﬁcient to produce clinically
signiﬁcant therapeutic effects. Various therapeutic strategies includ-
ing gene therapies have been employed to decrease VSMCs prolifera-
tion and reported to decrease intimal thickening in experimental
restenosis [1–3], however, optimal and promising gene therapy strat-
egies are still under investigation.
Thymidine phosphorylase (TP), also known as, platelet-derived
endothelial cell growth factor, catalyzes the reversible conversion of
thymidine to thymine and 2-deoxy‐D-ribose-1‐phosphate, and plays
a role in maintaining the nuclear pool of these molecules [4]. TP has
been widely studied in cancer biology as a proangiogenic factor,
however, whether and how it affects the cardiovascular system is
still not known. We previously demonstrated that direct injection of
1317H. Yue et al. / Biochimica et Biophysica Acta 1823 (2012) 1316–1323a plasmid vector encoding human TP cDNA into ischemic myocardi-
um or hindlimb promotes angiogenesis, arteriogenesis and inhibits
apoptosis [5–7]. We further found that gene transfer of TP into
VSMCs inhibits proliferation in vitro, and adventitial gene transfer of
human TP gene markedly decreased neointima hyperplasia in both
balloon injured rat carotid arteries and rabbit venous bypass graft
[8,9]. The mechanism underlying this phenotype is partly related to
TP mediated upregulation of heme oxygenase 1 (HO-1) and p27Kip1
expression [8,9]. Whether this effect is mediated by TP affected intra-
cellular signaling pathway is not clear.
The janus-activated kinase (JAK)/signal transducers and activators
of transcription (STAT) pathway is well known to be involved in
growth factor or cytokine induced VSMC proliferation and migration.
There are 7 members in the STAT family. All of which have been
reported to be expressed in VSMCs, and with the exception of
STAT2, all have been reported to show increased expression in the
balloon injured carotid artery wall [10–14]. A recent study using
siRNA showed that STAT1 is necessary for VSMC proliferation [13],
and Fludarabine, a chemotherapy drug, signiﬁcantly abolished VSMC
proliferation in vitro and reduced neointimal formation after balloon
injury in vivo associated with inhibition of STAT-1 activation [13].
However, other studies also indicated that activation of STAT1 is es-
sential for its inhibitory effect on VSMC proliferation [15,16]. Interest-
ingly, Bai et al. reported that interferon gamma induced pro-apoptotic
molecules XAF1 (X-linked inhibitor of apoptosis associated factor-1)
and Noxa in human VSMCs through STAT3 activation and that these
proteins sensitized VSMCs in vitro and in vivo to apoptosis triggered
via death receptor or mitochondrial mechanisms [17]. These data
suggest that STAT proteins may have dual-role on regulating VSMC
proliferation and function.
In this manuscript, we show that TP upregulates STAT3 gene ex-
pression via up-regulating STAT3 activation in VSMC through the
Src family kinase (SFK), Lyn. We found that TP induced expression
of STAT3 protein, but not tyrosine phosphorylation contributes to its
inhibitory effect on VSMC proliferation. We conclude that regulating
TP expression or activity may be a novel strategy in treating ischemic
cardiovascular diseases based on its proangiogenic and VSMC inhibi-
tory effects.2. Materials and methods
2.1. Vascular smooth muscle cell cultures
VSMCs were cultured from aortic arteries of male Sprague–
Dawley rats or C57BL6 mice using explant methods as mentioned be-
fore [5,8,18,19]. Cells were cultured in Dulbecco's modiﬁed Eagle's
medium (DMEM) supplemented with 10% fetal calf serum (FCS)
and 100 U/ml penicillin and 100 mg/ml streptomycin. All cells
showed “valley and hill” growth pattern when they were conﬂuent
and were positively stained for alpha-smooth muscle actin (Sigma),
a characteristic marker of VSMC (data not shown). The cells were in-
cubated at 37 °C in a 5% CO2 humidiﬁed atmosphere and maintained
at a sub-conﬂuent stage by subcultured with 0.025% trypsin/1 mmol/l
EDTA (Gibco, Carlsbad, CA). Wild-type rat and mouse VSMCs were
used from passages 3 to 12. TP overexpressing cell clone number 2
(C2) as well as empty vector-transfected control VSMC cells (PC)
has been established as described previously [8], which possess the
characters of VSMC as mentioned above.
The use of animals was in compliance with the Guidelines of the
Institutional Animal Care and Use Committee of the Faculty of
Medical Sciences, University of Fukui, and conforms to the Guide for
the Care and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85‐23, revised 1996). All
studies have been approved by the ethics committee of University
of Fukui.2.2. Gene transfection and knockdown
Phagemid vector pBK-RSV encoding human TP as well as K115E
(Lys-115–>Glu), L148R (Leu-148–>Arg) and R202S (Arg-202–
>Ser) mutant TP cDNA [20] were reversely transfected into 105
mouse VSMC in 6-well plate using Lipofectamine LTX Plus Regent
(Invitrogen). The cells were cultured for 72 h and then cell prolifera-
tion was assessed by cell counting. Mouse wild-type (wt) stat3 and
tyrosine 705 to phenylalanine mutant stat3 (Y705F-stat3) were
cloned into pcDNA6/Myc-His B as mentioned before [21]. These plas-
mid vectors were transfected into PC cells using Lipofectamine LTX
Plus Regent and cell clones was generated by selection with
Blasticidin (10 μg/ml). To further determine the function of STAT3
on VSMC, primary cultured mouse VSMC cells (passages 3) were
seeded at a concentration 1.5×105/well in 6-well plate, and cultured
overnight. The wt-stat3 and Y705F-stat3 as well as empty plasmid
vector pCDNA5/Myc-His B were then transfected into the cells using
Lipofectamine LTX Plus Regent and cell numbers were assessed 72 h
later. The parent VSMCs were used as control.
Pre-designed siRNA targeting rat Lyn gene was purchased from
Qiagen (Valencia, CA); and Silencer™ siRNA Transfection II Kit was
purchased from Applied Biosystems. A ﬁnal concentration of
30 nmol/l siRNA was transfected into 106 C2 cells in 10-cm plate
using a reverse transfection method based on the instruction of the
manufacturer. The cells were allowed to grow for 24 h, serum starved
for 24 h, and then re-stimulated with 10% FCS for another 24 h. The
cells were washed with cold PBS and then harvested for Western
blot assay. In some experiments, Lyn siRNA was transfected into C2
cell in 24-well plate, cultured for 3 days and cell proliferation was
assessed by 3-[4,5‐dimethylthiazol-2-yl]-2,5‐diphenyltetrazolium
bromide (MTT; Sigma Chemical, St. Louis, MO) assay.
2.3. Cell proliferation and survival assays
Cell proliferation and survival were assessed by MTT as previously
described and elsewhere [8,22], or by trypan blue staining based di-
rect cell counting using a hemocytometer, or counted with Z™ Series
COULTER COUNTER® (Beckman Coulter, Inc.) as indicated in the
results.
In some experiments, mouse VSMC were seeded in 12-well plate
(104/well), cultured overnight and then subjected to serum starva-
tion for 24 h. The cells were then stimulated with DMEM containing
1% FCS in the presence of C2 or PC cell lysates at a ﬁnal protein con-
centration of 40 μg/ml. The cells were cultured for 48 h and cell pro-
liferation was assessed with MTT assay. C2 and PC lysates were
prepared in sterile PBS by 3 frozen-thaw cycles, and protein concen-
tration was assessed with Bio-Rad Protein Assay kit (Bio-Rad).
2.4. Western blot assay
Cells were seeded at 106 per 10-cm plate and allowed to grow for
24 h. The cells were synchronized with serum‐free media for 24 h and
then stimulated with DMEM containing 10% FCS for the indicated
times. TP has no speciﬁc cell surface receptor. There was no intracel-
lular signaling pathway that mediates effect of TP has been demon-
strated. We thus used serum as a stimulator as it has multiple
simultaneous effects on kinase cascades. In some experiments, syn-
chronized cells were treated with Src inhibitor PP2 or its analog con-
trol PP3 or AG490 in the stimulating media for indicated times. Cells
were lysed in the ice-cold lysis buffer containing (in mmol/l): 20
Tris, pH 7.0, 2 EGTA, 5 EDTA, 30 NaF, 60 β-glycerophosphate, pH
7.2, 20 Na4P2O7.10H2O, 1 Na3VO4, 1% Triton X-100 and proteinase in-
hibitor cocktail (Roche R&D). To study STAT3 nuclear translocation,
cells were harvested with trypsin/EDTA, and cytosolic and nuclear
proteins were extracted with a Nuclear/Cytosol Fractionation kit
(BioVision, CA) as described before [18]. Thirty to ﬁfty microgram of
1318 H. Yue et al. / Biochimica et Biophysica Acta 1823 (2012) 1316–1323extract was subjected for immunoblot assay using antibodies to
total STAT3, phosphotyrosine705-STAT3, phosphoserine727-STAT3,
phospho-JAK2, JAK2, phospho-Src (Tyr416), phospho-Src (Tyr 527) as
well as Fyn (all are from Cell Signaling), or to Lyn (SC-7274, Santa
Cruz), actin (SC-1616R), alpha-tubulin (SC-8035), and TP (SC-9523),
or to TATA-binding protein (abcam) and 4 G10 Anti-phosphotyrosine
(Millipore) antibodies. Synchronized and serum‐stimulated cells were
also subjected for immunoprecipitation–immunoblotting assay as
mentioned anywhere [21,23,24].
2.5. Real-time PCR‐based mRNA quantitative assay
Synchronized VSMCs were treated with 10% FCS for 3 h and then
total RNA was extracted from VSMCs using RNeasy Mini Kit (QIAGEN).
One microgram of the total RNAwas treated with DNase I, and used for
cDNA construction using AMV First Strand cDNA Synthesis Kit for RT-
PCR (Roche). Real-time PCR for STAT3 was performed using SYBR
Green PCR Master Mix (Applied Biosystems) with an iCycler iQ Real-
Time PCR detection system [18,25]. The forward primer for rat STAT3
was: 5′-GAG CTG GCT GAC TGG AAG AGG-3′, and the reverse primer
was: 5′-TTG TTG GCG GGT CTG AAG TTG-3′.
2.6. Statistical analysis
All of the presented data were from at least 3 independent exper-
iments, except where indicated in the text. Results are expressed as
the mean±SEM. Statistical analysis was performed using One-way
ANOVA (StatView 5.0) or unpaired t test as appropriate. A value of
pb0.05 was considered statistically signiﬁcant.
3. Results
3.1. TP activity is necessary for TP inhibited VSMC proliferation
We previously have shown that TP inhibitor, TPI, increase C2 pro-
liferation but had no effect on PC, suggesting that TP activity is neces-
sary for its inhibitory effect on VSMC. To exclude the potentiality that
the slowed growth of C2 is due to an artiﬁcial effect of constitutive
gene overexpression, mouse primary cultured VSMC was transfected
with phagemid vector encoding human TP cDNA or K115E-, L148R-
and R202S-mutant TP cDNA for 72 h and then cell numbers were
counted with Z™ Series COULTER COUNTER®. The mutations of TP0
5
10
15
20
25
30
35
40
45
pR
K-
RS
V
pR
K-
RS
V/
TP
pR
K-
RS
V/
K1
15
E-T
P
pR
K-
RS
V/
L1
48
R-
TP
pR
K-
RS
V/
R2
02
S-T
P
*
A
Ce
ll 
nu
m
be
rs
 (x
 10
4 )
Fig. 1. TP activity is necessary for its inhibitory effect on VSMC proliferation. A. Phagemid ve
and R202S (Arg-202–>Ser) mutant TP were reversely transfected into 105 mouse primary
were counted 72 h later with Z™ Series COULTER COUNTER®. N=3 for each transfection. *p
well plate, cultured for overnight and then subjected for serum starvation for 24 h. The cell
proliferation was assessed with MTT assay. N=4 for each condition.on these sites have been reported to completely diminish TP activity
[20]. As shown in Fig. 1A, in comparing to the empty vector‐trans-
fected VSMC, all of the TP mutants did not have signiﬁcant effect on
cell proliferation. However, similar to rat VSMC, wild‐type TP trans-
fection dramatically inhibited mouse VSMC growth. We also treated
mouse VSMC with culture media in the presence of C2 or PC cell ly-
sates. In comparing to serum alone, PC lysate had no effect on
mouse VSMC growth; however, C2, which has high TP activity [8],
dramatically inhibited cell proliferation (Fig. 1B). These data is in
line with our previous ﬁnding [8], clearly demonstrated that the
inhibitory effect of TP on VSMC proliferation is dependent on its enzy-
matic activity.
3.2. TP increased STAT3 phosphorylation and expression in VSMC
Since STAT3 signaling is involved in growth factor and cytokine in-
duced VSMC proliferation and migration, we examined whether TP
has effects on signaling pathway involving STAT3. Serum starvation
and re-stimulation induced STAT3 tyrosine-705 phosphorylation
(p-Y-STAT3) as well as serine-727 phosphorylation (p-S-STAT3)
were examined. P-Y-STAT3 was in same level in C2 and PC cells
after serum starvation for 24 h (Fig. 2A, 0 min). Serum did not inﬂu-
ence p-Y-STAT3 in PC cells, however, unexpectedly, signiﬁcantly in-
creased p-Y-STAT3 in C2 cells. The p-Y-STAT3 was increased within
5 min, reached to maximal level after 1 hr, and then gradually de-
creased. The level of p-Y-STAT3 was higher in C2 than in PC at all of
the examined time points (Fig. 2A and B). P-S-STAT3 was higher in
PC than in C2 after serum starvation for 24 h (4–5 folds). Serum stim-
ulation signiﬁcantly induced p-S-STAT3 in both cells as early as 5 min
and the relative fold changes were markedly higher in C2 than in PC
(Supplementary Fig. IA). However, the total amount at each time
point was similar between C2 and PC. The p-S-STAT3 reached to
peak in both cells around 15–30 min after stimulation and then grad-
ually decreased and returned to the basal level in both cells after 24 h
(Fig. 2B). There were no differences in T-STAT3 expression after the
short term serum stimulation (Fig. 2A and Supplementary Fig. IB),
but it signiﬁcantly increased in C2 cell than in PC 24 h later
(Fig. 2B). Nuclear and cytosolic fractionation revealed that p-Y-
STAT3 in C2 nuclei was far greater than in PC after serum stimulation
for 24 h (Fig. 2C). The P-S-STAT3 was similar between C2 and PC in
the nucleus. While there was no signiﬁcant difference in detectable
phosphorylated STAT3 (Y705 or Ser727) in the cytosolic fractions0.02
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JAK2 plays an important role in the activation of STATs, and recent
reports demonstrated a nuclear localization of JAK1 and JAK2, which
is associated with high rates of cell growth [26,27]. Serum only in-
duced weak JAK2 phosphorylation in both C2 and PC cells; however,
there was no difference at each examined time points between cells
(Fig. 3A). There was no difference in JAK2 phosphorylation between
C2 and PC cells in nuclear fraction after serum stimulation for 24 h
(Fig. 3B). Treatment of cells with AG490, a JAK2 inhibiter, also did not
alter serum‐stimulated STAT3 phosphorylation (Fig. 3C), suggesting
that TP induced p-Y-STAT3 was JAK2 independent.
3.4. TP induces STAT3 activation via Lyn
SFK has been reported to directly activate STAT3 [28–30]. To de-
termine whether SFK is responsible for the STAT3 activation in C2
cells, synchronized cells were stimulated with 10% FCS in the pres-
ence of PP2, a potential SFK inhibitor, for 24 h. PP3, an analog of
PP2, treated cells were used as controls. As shown in Fig. 4A, PP3
did not inﬂuence serum‐stimulated STAT3 phosphorylation, however,
PP2 signiﬁcantly decreased p-Y-STAT3 in C2 cell, but has no effect on
PC cells. Src activity is regulated by tyrosine phosphorylation at two
sites with opposing effects. Phosphorylation of Tyrosine (Tyr)416 in
the activation loop of the kinase domain by carboxy-terminal Src ki-
nase (Csk) upregulates enzyme activity. Phosphorylation of Tyr527
in the carboxy-terminal tail renders the enzyme less active [31,32].D
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was transfected into C2 cells, and Lyn expression was assessed 72 h later, n=3. E. Lyn siRN
stimulated with 10% FCS for another 24 h. Whole cell lysate was analyzed by Western blot
experiments. F. 2000 C2 cells in 24-well plate were reversely transfected with Lyn siRNA foBy immunoblotting assays we demonstrated that Src was phosphory-
lated at Tyr527 but not at Tyr416 site in C2, suggesting that its activity
was lower in C2 than in PC cells (Fig. 4B). Therefore Src should not be
involved in TP induced STAT3 tyrosine phosphorylation. Total amount
of Fyn was also lower in C2 than in PC (Fig. 4B). We thus immuno-
precipitated Lyn, another SFK member, and performed immunoblot
assay using anti-phosphotyrosine antibody (4G10) to determine its
phosphorylation status. Serum had no effect on Lyn phosphorylation
in PC cells, but signiﬁcantly increased tyrosine phosphorylated Lyn
in C2 cells (Fig. 4C). These data suggested that Lyn may be involved
in the TP induced STAT3 tyrosine phosphorylation. To test this hy-
pothesis, a speciﬁc Lyn siRNA was used to knockdown Lyn expression
in C2 cells (Fig. 4D). Interestingly, knockdown of Lyn expression sig-
niﬁcantly decreased serum induced STAT3 tyrosine phosphorylation
(Fig. 4E), and increased C2 cell proliferation (Fig. 4F). This ﬁnding
suggested that Lyn plays a critical role in TP inhibited VSMC
proliferation.
3.5. STAT3 protein but not STAT3 phosphorylation is necessary for TP
inhibited VSMC proliferation
Recent studies have demonstrated that U-STAT3 regulates a set of
genes and plays important roles in regulating pathophysiological re-
sponses [21,33–35]. U-STAT3 also possesses anti-inﬂammatory ef-
fects, suggesting that U-STAT3 might be a natural antagonist of the
pro-inﬂammatory phospho-STAT3 [36]. We thus hypothesized
that U-STAT3 might inhibit VSMC proliferation. To examine thisp-Y-STAT3
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be phosphorylated at the 705-tyrosine site [21], were transfected
into PC cells. Two cell clones that over expressed wt-stat3 and
Y705F-stat3 and had similar level of total STAT3 expression
(Fig. 5A) were used for proliferation assay. Surprisingly, either direct
cell counting or MTT assay demonstrated that both thewt and Y705F-
stat3 gene transfection markedly decreased PC proliferation to the
level of C2 cells (Fig. 5B and C). These data suggest that TP induced ac-
cumulation of U-STAT3 may contribute to the decreased proliferation
in C2 cells, which is independent to Y705 phosphorylation status. This
ﬁnding was further conﬁrmed by transfection of the above plasmid
vectors into mouse primary cultured VSMCs. As shown in Fig. 5D, in
comparing to parent VSMCs (No transfection), empty vector
pCDNA6B did not affect VSMCs proliferation. However, pCDNA6B/
wt-stat3 or pcDNA6B/Y705F-stat3 dramatically inhibited mouse
VSMCs proliferation.
4. Discussion
Obstructive and thrombotic cardiovascular diseases are the most
common cause of death and disability in the developed world. The
etiology of these disorders is multi-factorial and involves complex in-
terplay between lifestyle and ﬁxed causative factors [37]. An initiating
step is often vascular injury induced by cellular oxidative stress pre-
cipitated by the production of damaging reactive oxygen species bySTAT3
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and ﬁnally induced both thrombotic and non-thrombotic occlusion
of the vessel. VSMCs are the major cell population in the arterial
wall, and changes in their behavior, function and redox status con-
tribute to alterations in vascular remodeling and cell signaling. An ex-
tensive body of experimental medicine has demonstrated that
targeting VSMC proliferation and migration may achieve a signiﬁcant
therapeutic effect in these diseases [1–3,8,9,38]. However, developing
novel mechanism-based targets for intervention in these diseases re-
mains a high priority.
TP has been found in atherosclerotic plaque [39], and its expres-
sion is suggested to correlate with the plaque angiogenesis which
might contribute to plaque growth, and risk of rupture. However,
plaque angiogenesis may not in fact be a requirement for atherogen-
esis, but rather a physiological response to the pathophysiological
state of the arterial wall [40]. By treating the mouse VSMCs with
high TP activity containing cell lysate or gene transfection of lose-
function of mutant TP into VSMCs (Fig. 1), we clearly demonstrated
that high TP activity inhibits VSMC proliferation. Our data suggest
that the higher TP activity in atherosclerotic plaque may contribute
to attenuate vessel wall VSMC response to the pathophysiological
stimulation.
TP has noticeable effects on angiogenesis that has been clearly
demonstrated. One concern raised here is how TP inhibits VSMC pro-
liferation but enhances angiogenesis. VSMC are necessary for0
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maturation. The mechanisms by how the vessel wall formation and
lumen formation are controlled are only partially understood. Thera-
peutic stimulation of arteriogenesis with cytokines or genes has been
successfully performed in experimental animal models. Translation
into clinical practice, however, has hitherto been problematic. The
reasons are multiple. Uncontrolled smooth muscle cell proliferation
induces vascular occlusion and is lethal [41], which might be one of
the reasons that caused the failure of these novel developed thera-
peutic strategies. Balanced and controlled VSMC proliferation might
be a key control point in atherosclerosis and arteriogenesis. Our pre-
vious studies have demonstrated that TP gene injection enhanced
both angiogenesis and arteriogenesis in ischemic hearts and hind
limbs [5–7]. TP may play a role in balancing and controlling the
VSMC growth during arteriogenesis as well as vascular maturation.
In this study, we discovered that TP induced not only STAT3 acti-
vation but also total STAT3 accumulation in VSMCs (Fig. 2). Cell ly-
sates containing high TP activity is sufﬁcient to induce STAT3
tyrosine phosphorylation (Supplementary Fig. II), but dramatically
inhibited VSMC proliferation (Fig. 1B). In contrary to this ﬁnding,
a recent study showed that inhibition of STAT3 signaling prevented
VSMC proliferation and inhibited neointimal formation [42]. WP1066,
a compound induces VSMC apoptosis associated with inhibition of
STAT3 signaling, was used to examine effect of STAT3 inhibition on
VSMC proliferation in vitro [42]. In addition, a C57Bl6 mouse strain,
which has been widely known to be resistance to guide wire induced
neointima formation [43], was used to examine the effect of WP1066
on neointimal hyperplasia in vivo. Therefore, data generated from this
study should be interpreted with caution. STAT3 has GAS motif in its
promoter region, which is a binding site of p-Y-STAT3. Serum stimula-
tion also increased expression of STAT3 in RNA level, suggesting that
TP induced accumulation of U-STAT3 protein was resulted from
the phospho-STAT3 upregulated transcription of STAT3 gene. Phos-
phorylation on Ser727 is indispensable for STAT3 maximal tran-
scriptional activity [44]. Although the fold change of p-S-STAT3
was higher in C2 after serum stimulation, it returned to the basal
level 24 h later and showed a relative lower level of total amount
in the whole cell lysate of C2, suggesting that its activity is not relat-
ed to the decreased C2 proliferation.
STAT proteins participate in a wide variety of physiological pro-
cesses and direct seemingly contradictory responses, such as prolifer-
ation and apoptosis. The classical model for STAT activation has been
identiﬁed and characterized in which STATs bind through phos-
photyrosine/SH2-domain interactions and are then phosphorylated
by JAK2 [45]. The phosphorylated STATs then dimerize and translo-
cate to the nucleus to regulate expression of their targeting genes.
However, our data suggested that JAK2 is not involved in TP induced
p-Y-STAT3, but Lyn plays a priority role. Src family tyrosine kinases
are signaling intermediates in a diverse array of cellular events in-
cluding cell differentiation, motility, proliferation, and survival [46].
Lyn has been described to have an inhibitory role in myeloid lineage
proliferation [47]; however, surprisingly, little is known about its ef-
fect on VSMC. Here, we demonstrated that Lyn may negative regulate
cell proliferation in TP overexpressing VSMCs. Many phospho-
STAT3 targeting genes are known, including genes encoding the
anti-apoptotic proteins (e.g. Bcl-xl, Mcl-1, and Bcl-2), proliferation as-
sociated proteins (e.g. Cyclin D1 and Myc), and proangiogenic factor
(e.g. VEGF) [48–55], as well as antioxidant enzymes such as HO-1
[56], which has been found to be upregulated by TP in our previous
studies [8,9]. Therefore, the current paper supports our previous ﬁnd-
ing and that TP induced phospho-STAT3 may contribute to the higher
HO-1 expression in C2 cells. In contrast to its proliferative and devel-
opmental effects, STAT3 also enhances apoptosis in response to death
stimulation [17], suggesting the intricacy of STATs family in inﬂuenc-
ing VSMC function. However, this pro-apoptotic effect could not ex-
plain our ﬁnding as we did not ﬁnd an enhanced apoptosis undernormal culture condition as well as any of the mentioned treatments
in both cells.
By using conditional knockout mice, STAT3 has been revealed
playing pleiotropic roles and showing that there is an essential
Stat3-dependent function that is not mediated by any of the known
Stat3-activating cytokines or their receptors [57]. Recent studies
demonstrated that unphosphorylated STATs can enter nuclei and in-
duce “renegade” gene expression [21,33,35,58]. Though nuclear-
cytoplasmic shuttling of unphosphorylated STAT1 has been known
for a decade [59], and U-STAT3 has been found to be functional
about 6 years ago [35], how unphosphorylated STATs regulate gene
expression is still unknown. We have found that connective tissue
growth factor (CTGF), which promotes VSMC proliferation, is a target
of U-STAT3 [21], and U-STAT3 negatively regulates CTGF expression
at protein level in HEK293 cells (YH, unpublished data). However,
we don't know whether CTGF plays a role in U-STAT3 induced inhibi-
tion of VSMC proliferation. Further studies are necessary to determine
the mechanism and the potential downstream pathways that mediate
the effect of U-STAT3 on VSMC proliferation.
In summary, our study ﬁrst demonstrated that TP induced STAT3
phosphorylation and increased total amount of U-STAT3 in VSMC,
which may play a critical role in inhibiting VSMC proliferation. Our
data provide novel insights into the role of TP in the cardiovascular
system.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2012.05.025.
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